Literature DB >> 9285685

Pertubation of B and T cell development and predisposition to lymphomagenesis in Emu Bmi1 transgenic mice require the Bmi1 RING finger.

M J Alkema1, H Jacobs, M van Lohuizen, A Berns.   

Abstract

Proviral activation of the Bmi1 gene has implicated Bmi1 as a collaborator of c-Myc in lymphomagenesis. To determine the effect of Bmi1 overexpression on hematopoiesis and lymphomagenesis transgenic mice were generated that overexpress different forms of the Bmi1 protein in their lymphoid compartment. Emu Bmi1 transgenic mice, overexpressing the wild type Bmi1 protein showed a perturbed lymphoid development and were highly susceptible to B and T cell lymphomagenesis. Mutational analysis of the Bmi1 protein demonstrated that the conserved N-terminal RING finger and central part of Bmi1 are essential for its oncogenic potential whereas the C-terminal Pro-Ser rich region is not required. We have used provirus tagging in the Emu Bmi1 mice to identify genes that cooperate with Bmi1 in lymphomagenesis. MoMLV infection in Emu Bmi1 transgenic mice accelerated lymphoma development. Proviral activation of the Pim and Myc genes but not the Gfi1 gene were frequently observed in these tumors. These results demonstrate that Bmi1 is a potent oncogene and suggest that it plays an important role in early lymphoid development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285685     DOI: 10.1038/sj.onc.1201262

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

1.  Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation.

Authors:  Anna V Molofsky; Ricardo Pardal; Toshihide Iwashita; In-Kyung Park; Michael F Clarke; Sean J Morrison
Journal:  Nature       Date:  2003-10-22       Impact factor: 49.962

2.  Site-specific expression of polycomb-group genes encoding the HPC-HPH/PRC1 complex in clinically defined primary nodal and cutaneous large B-cell lymphomas.

Authors:  Frank M Raaphorst; Maarten Vermeer; Elly Fieret; Tjasso Blokzijl; Danny Dukers; Richard G A B Sewalt; Arie P Otte; Rein Willemze; Chris J L M Meijer
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

Review 3.  Bmi1, stem cells, and senescence regulation.

Authors:  In-Kyung Park; Sean J Morrison; Michael F Clarke
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

4.  Impaired maturation of myeloid progenitors in mice lacking novel Polycomb group protein MBT-1.

Authors:  Satoko Arai; Toru Miyazaki
Journal:  EMBO J       Date:  2005-05-05       Impact factor: 11.598

5.  Targeting of BMI-1 with PTC-209 inhibits glioblastoma development.

Authors:  Yu Kong; Chunbo Ai; Feng Dong; Xianyou Xia; Xiujuan Zhao; Chao Yang; Chunsheng Kang; Yan Zhou; Qian Zhao; Xiujing Sun; Xudong Wu
Journal:  Cell Cycle       Date:  2018-07-23       Impact factor: 4.534

6.  Identification of a polymorphism in the RING finger of human Bmi-1 that causes its degradation by the ubiquitin-proteasome system.

Authors:  Jie Zhang; Kevin D Sarge
Journal:  FEBS Lett       Date:  2009-02-20       Impact factor: 4.124

Review 7.  Molecular pathogenesis of MLL-associated leukemias.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

8.  The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.

Authors:  Sivaprakasam Balasubramanian; Gautam Adhikary; Richard L Eckert
Journal:  Carcinogenesis       Date:  2009-12-16       Impact factor: 4.944

9.  MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer.

Authors:  Resham Bhattacharya; Milena Nicoloso; Rochelle Arvizo; Enfeng Wang; Angelica Cortez; Simona Rossi; George A Calin; Priyabrata Mukherjee
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

10.  PTEN inhibits BMI1 function independently of its phosphatase activity.

Authors:  Catherine Fan; Lizhi He; Anil Kapoor; Adrian P Rybak; Jason De Melo; Jean-Claude Cutz; Damu Tang
Journal:  Mol Cancer       Date:  2009-11-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.